Ultragenyx Pharmaceutical
RARE
#3663
Rank
HK$27.31 B
Marketcap
HK$283.10
Share price
-0.44%
Change (1 day)
-23.15%
Change (1 year)

Revenue for Ultragenyx Pharmaceutical (RARE)

Revenue in 2025 (TTM): HK$4.91 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current revenue (TTM ) is HK$4.90 Billion. In 2024 the company made a revenue of HK$4.34 Billion an increase over the revenue in the year 2023 that were of HK$3.39 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Ultragenyx Pharmaceutical from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$4.91 B13.01%
2024 HK$4.34 B28.24%
2023 HK$3.39 B19.47%
2022 HK$2.83 B3.6%
2021 HK$2.74 B30.41%
2020 HK$2.10 B160.12%
2019 HK$0.80 B100.31%
2018 HK$0.40 B1876.01%
2017 HK$20.4 M1878.7%
2016 HK$1.03 M
2015 N/A
2014 N/A
2013 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
BioMarin Pharmaceutical
BMRN
HK$24.07 B 390.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
HK$4.65 B-5.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
HK$2.36 B-51.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
HK$0.55 B-88.76%๐Ÿ‡บ๐Ÿ‡ธ USA